iX Biopharma Ltd. (42C) AI Stock Analysis

• Market Cap: S$197.93M
• Dividend Yield: N/A
• Average Volume (3M): 15.11M
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: 30.34%
• EPS Growth: 17.14%
• Country: SG
• Employees: 35
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 1,036,295,900
• 10 Day Avg. Volume: 11,332,920
• 30 Day Avg. Volume: 15,113,843
• PEG Ratio: 0.08
• Price to Book (P/B): 38.32
• Price to Sales (P/S): 1.80
• P/FCF Ratio: -3.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: S$0.22 ▲(55.71% Upside)
• Action: Reiterated Date: 02/06/26
• Date: Action: Reiterated 02/06/26

The score is held down primarily by very weak financial performance (persistent losses, high leverage, and negative cash flows). Technicals are a relative positive with price above key moving averages and a positive MACD, but valuation is constrained by loss-making earnings and no dividend support.

Positive Factors

Proprietary delivery platform

Owning the WaferiX sublingual wafer platform gives the company a durable product differentiation. A platform technology can be applied across multiple therapeutics, enabling recurring licensing, easier product extensions and manufacturing leverage that support long-term commercial scalability and partner interest.

Partner-driven commercialization model

A business model built on licensing, partnerships and contract manufacturing reduces capital intensity and shifts commercialization risk to partners. Durable benefits include access to established distribution, milestone and royalty income, and scalable revenue with lower fixed selling costs if partnerships are executed.

Improving product-level economics

An improving gross margin alongside modest revenue growth indicates the core wafer products can generate positive unit economics. If management controls operating expenses, stronger gross margins provide a sustainable path to profitability over months as scale and partner rollouts reduce per-unit costs.

Negative Factors

Persistent large losses

Very large and persistent net losses undermine retained capital and strategic flexibility. Over the medium term these losses pressure ability to self-fund R&D, regulatory submissions and commercial rollouts, forcing dependence on external financing which can dilute shareholders and constrain long-term planning.

High financial leverage

Extremely high debt relative to equity increases refinancing and interest-risk. High leverage reduces free cash flow available for investment, raises default vulnerability in adverse cycles, and limits capacity to fund new trials or scale manufacturing without costly external capital.

Negative operating and free cash flow

Ongoing negative operating and free cash flows with declining FCF growth indicate structural cash burn. This erodes runway for regulatory approvals and market launches, forces repeated financing rounds, and restricts the company’s ability to invest in commercialization or expand manufacturing capacity long term.

iX Biopharma Ltd. Business Overview & Revenue Model

Company Description

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, and insomnia. The company is also developing Wafermine, a racemic ketamine sublingual wafer, which has completed phase-2 clinical trial for the treatment of complex regional pain syndrome, as well as psychiatric conditions, including depression; iXB 401, a sublingual semaglutide wafer that is in pre-clinical development for the treatment of Type 2 Diabetes and Obesity; SL-NAD+, a sublingual NAD+ wafer to increase the body's NAD+ levels, energy levels, and alertness; iXB 120 that has completed Phase I clinical trial for acute agitation; IXB-214, which has completed Phase I clinical trial for complex regional pain syndrome; and IXB-314 that has completed Phase I clinical trial for treatment resistant depression. In addition, it develops BnoX that is in a phase-1 clinical trial for moderate to severe pain; NAD+ for sarcopenia; iXB 321, an influenza vaccine; iXB 322, a novel low-dose interferon sublingual wafe for respiratory viral prophylaxis; and LumeniX, a sublingual glutathione wafer for skin brightening and immunity. iX Biopharma Ltd. was incorporated in 2004 and is headquartered in Singapore.

How the Company Makes Money

iX Biopharma generates revenue through the development and commercialization of its proprietary drug products, which include both prescription and over-the-counter medications. The company's revenue model includes direct sales of its products, licensing agreements, and partnerships with pharmaceutical companies for the distribution and marketing of its formulations. Additionally, iX Biopharma may receive milestone payments and royalties from collaborations that leverage its drug delivery technology. Key partnerships with industry players and continuous investment in research and development contribute significantly to its revenue streams.

iX Biopharma Ltd. Financial Statement Overview

Summary

Financials are weak overall: persistent losses with a deeply negative net margin (-130.57%), high leverage (debt-to-equity 16.17) and negative ROE (-27.78%), plus negative operating and free cash flow and declining free cash flow growth (-18.61%).

Income Statement

The income statement reveals significant challenges, with consistent negative net income and declining EBIT and EBITDA margins. Despite a slight revenue growth of 5.19% in the latest year, the company struggles with profitability, as evidenced by a negative net profit margin of -130.57%. The gross profit margin improved to 26.26%, but overall, the financial health remains weak.

Balance Sheet

The balance sheet indicates high leverage, with a debt-to-equity ratio of 16.17, suggesting significant financial risk. The return on equity is negative at -27.78%, reflecting poor returns for shareholders. The equity ratio is low, indicating a heavy reliance on debt financing, which could be risky if not managed properly.

Cash Flow

Cash flow analysis shows negative operating and free cash flows, with a concerning free cash flow growth rate of -18.61%. The operating cash flow to net income ratio is negative, indicating cash flow issues. The free cash flow to net income ratio is slightly positive at 1.05, but overall cash flow management appears weak.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	7.77M	5.96M	5.91M	14.39M	1.75M
Gross Profit	2.04M	1.05M	2.32M	12.29M	-382.00K
EBITDA	-8.96M	-8.68M	-8.51M	-2.84M	-10.79M
Net Income	-10.14M	-10.79M	-9.62M	-4.60M	-8.23M
Balance Sheet
Total Assets	11.28M	14.62M	24.93M	28.52M	18.86M
Cash, Cash Equivalents and Short-Term Investments	866.00K	1.77M	6.52M	13.49M	6.21M
Total Debt	5.90M	5.20M	4.34M	4.41M	4.24M
Total Liabilities	10.92M	10.28M	9.08M	8.77M	7.15M
Stockholders Equity	365.00K	4.34M	15.85M	19.74M	11.71M
Cash Flow
Free Cash Flow	-3.96M	-6.84M	-8.36M	2.92M	-8.90M
Operating Cash Flow	-3.76M	-6.55M	-7.66M	3.12M	-8.35M
Investing Cash Flow	-201.00K	1.06M	-695.00K	-5.62M	-507.00K
Financing Cash Flow	3.12M	724.00K	1.42M	9.79M	10.02M

iX Biopharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.14
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SG:42C, the sentiment is Neutral. The current price of 0.14 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.18, and above the 200-day MA of 0.08, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 47.12 is Neutral, neither overbought nor oversold. The STOCH value of 3.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SG:42C.

iX Biopharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
42C	48 Neutral	S$197.93M	-28.94	-431.07%	―	30.34%	17.14%

iX Biopharma Ltd. Corporate Events

iX Biopharma Wins US$41 Million U.S. Contract to Advance Wafermine Pain Therapy

iX Biopharma has secured a US$40.95 million development contract from the U.S. Government, represented by the Defense Health Agency and Program Executive Office Operational Medical Systems, to advance its Wafermine sublingual ketamine wafer for acute moderate to severe pain. The funding underscores Wafermine’s perceived strategic value as a non-opioid pain treatment for both commercial use and U.S. military medical needs.

the programme will finance efforts to obtain an Emergency Use Authorization from the FDA, enabling the U.S. Department of Defense to use Wafermine before full regulatory approval, and will support Phase 3 development toward a New Drug Application. The sole-source award, based on the government’s assessment that iX Biopharma is uniquely capable of delivering the product on the required timeline, positions the company for potential future procurement if Wafermine is adopted into standard issue medical sets for the Joint Force.

The most recent analyst rating on (SG:42C) stock is a Hold with a S$0.19 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.

iX Biopharma Wins US$41 Million U.S. Defense Contract for Non-Opioid Pain Drug

iX Biopharma has secured a US$40.95 million development contract from the U.S. Department of Defense to advance Wafermine, its patented sublingual ketamine wafer for acute moderate to severe pain, through Phase 3 clinical trials. The funding will also support efforts to obtain a U.S. Food and Drug Administration Emergency Use Authorization for Department of Defense use over a 36‑month period.

Awarded via a sole-source procurement, the contract underscores the U.S. Government’s view that iX Biopharma is uniquely positioned to deliver this non-opioid, rapidly acting pain treatment based on its proprietary technology and advanced development status. The deal validates Singapore’s biotech capabilities and is expected to bolster iX Biopharma’s global positioning, with Wafermine aimed at both near-term military deployment and longer-term commercial use in civilian healthcare settings.

The most recent analyst rating on (SG:42C) stock is a Hold with a S$0.19 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.

iX Biopharma to Raise At Least S$6 Million via Share Placement

iX Biopharma has entered into a placement agreement with Oversea-Chinese Banking Corporation to raise at least S$6 million through a non-underwritten share placement. The deal will see new ordinary shares offered at S$0.198 each to institutional and accredited investors in Singapore under an exempt offering structure.

iX Biopharma expects to issue a minimum of 30,303,100 new shares, representing about 3.16% of its current share capital and 3.06% of its enlarged capital post-placement. The company has also included an upsize option for additional shares, and the new stock will be freely transferable and rank pari passu with existing shares, modestly diluting current shareholders while bolstering capital resources.

The most recent analyst rating on (SG:42C) stock is a Hold with a S$0.19 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.

iX Biopharma Earns Third Spot on Singapore’s Fastest Growing Companies List

iX Biopharma has been named one of Singapore’s Fastest Growing Companies 2026 by The Straits Times and Statista, marking the third time it has received this recognition after earlier listings in 2023 and 2024, underscoring its strong revenue growth and business resilience. The company attributes its momentum to its WaferiX drug delivery platform and is pursuing a capital-light expansion strategy in the United States, including a proprietary digital platform targeting the longevity segment, a move that positions it for scalable long-term growth and reinforces its industry standing among high-growth healthcare innovators.

The most recent analyst rating on (SG:42C) stock is a Sell with a S$0.18 price target. To see the full list of analyst forecasts on iX Biopharma Ltd. stock, see the SG:42C Stock Forecast page.